James Yu
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2015 | Hanyang University College of Medicine, Seoul, KR, MD |
Postgraduate Training
| 2022-2025 | Postgraduate Fellow, Hematology/Oncology, Moffitt Cancer Center/University of South Florida, Tampa, Florida |
| 2019-2022 | Resident, Internal Medicine, Adventhealth Orlando, Orlando, Florida |
Licenses & Certifications
| 2025 | Medical License |
| 2022 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Chief Fellow, Moffitt Cancer Center/University of South Florida, Tampa, Florida, 2024 - 2025
Honors & Awards
| 2025 - Present | Best Clinician Award, Moffitt Cancer Center Fellowship Program |
| 2025 - Present | 2025 Robert A. Good Honor Society, University of South Florida |
| 2025 - Present | 2025 NCCN Oncology Fellows Program & Annual Conference – Institutional Nominee |
| 2024 - Present | 2024 AACR/ASCO Methods in Clinical Cancer Research Workshop |
| 2024 - Present | Moffitt Annual Symposium Oral Presentation Award, Moffitt Cancer Center |
| 2023 - Present | 2023 STOFF Society for Translational Oncology Fellows’ Forum Workshop |
| 2023 - Present | 2023 ASCO Annual Meeting, Conquer Cancer Merit Award, ASCO |
| 2022 - Present | 2022 Outstanding Accomplishment in Research Award, Adventhealth Orlando |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yu, J, Laborde, JM, Park, R, Shahzad, M, Kim, YC, Cheon, J, Imanirad, I, Kim, RD, De Castria, TB, Nardella, NL, Malafa, M, Denbo, JW, Fleming, JB, Hoffe, S, Frakes, JM, Sinnamon, AJ, Pimiento, J, Hodul, PJ, Kim, DW. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Cancers 17(11), 2025. e-Pub 2025. PMID: 40507279.
- Shahzad, M, Amin, MK, Khalid, MF, Kasaeian, A, Oskouie, IM, Yu, J, Warraich, SZ, Basharat, A, Butt, A, Zaidi, M, Anwar, I, Jaglal, M, Mushtaq, MU. Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Myeloid Neoplasms. Clinical Lymphoma, Myeloma and Leukemia 25(5):e319-e335, 2025. e-Pub 2025. PMID: 39890517.
- Shahzad, M, Iqbal, Q, Amin, MK, Kasaiean, A, Oskouie, IM, Warraich, SZ, Yu, J, Anwar, I, Jaglal, M, Mushtaq, MU. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older. Transplantation and Cellular Therapy 31(3):172.e1-172.e13, 2025. e-Pub 2025. PMID: 39755255.
- Yu J, He AR, Ouf M, Mehta R, Anaya DA, Denbo J, Bridges C, Tin A, Aushev VN, Palsuledesai CC, Sharma S, Jurdi A, Liu MC, Kim RD. Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection. JCO Precis Oncol 9:e2400443, 2025. e-Pub 2025. PMID: 39772829.
- Yu J, Park R, Miao R, Imanirad I, Shahzad M, Laborde JM, Knepper TC, Walko CM, Kim R. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. J Immunother 47(9):378-383, 2024. e-Pub 2024. PMID: 39012081.
- Mohammed, T, Yu, J, Qiao, Y, Kim, YC, Mortensen, E, Swede, H, Wu, Z, Zhang, J. Marijuana Use May Be Associated with Reduced Prevalence of Prostate Cancer. Biomedicines 12(5), 2024. e-Pub 2024. PMID: 38790970.
- Yu J, Avriett TA, Ray CM, Kim RD. Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report. J Gastrointest Oncol 15(1):485-490, 2024. e-Pub 2024. PMID: 38482231.
- Kim DW, Kim YC, Kovari BP, Martinez M, Miao R, Yu J, Mehta R, Strosberg J, Imanirad I, Kim RD. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel) 16(3), 2024. e-Pub 2024. PMID: 38339307.
- Miao R, Kim DW, Yu J, Malafa M, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab. Oncology 102(7):549-555, 2024. e-Pub 2024. PMID: 38061339.
- Guo, M, Liu, J, Miao, R, Ahmed, Z, Yu, J, Guan, J, Ahmad, S, Zhou, S, Grove, A, Manoucheri, M, Socinski, MA, Mekhail, T. A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy 45(9):389-395, 2022. e-Pub 2022. PMID: 36066505.
- Yu J, Diaz JD, Goldstein SC, Patel RD, Varela JC, Reyenga C, Smith M, Smith T, Balls J, Ahmad S, Mori S. Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections. Transplant Cell Ther 27(6):500.e1-500.e6, 2021. e-Pub 2021. PMID: 33849818.
- Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Br J Cancer 124(11):1803-1808, 2021. e-Pub 2021. PMID: 33828254.
- Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist 25(12):e1893-e1899, 2020. e-Pub 2020. PMID: 32776632.
Review Articles
- Miao, R, Yu, J, Kim, RD. Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361439.
- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw 23(5), 2025. e-Pub 2025. PMID: 40341124.
- Yu J, Park R, Tojjari A, Sadeghipour A, Saeed A, Saeed A. Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor-comprehensive review of early safety & efficacy data. Expert Opin Investig Drugs 33(9):887-895, 2024. e-Pub 2024. PMID: 39099411.
- Park, R, Yu, J, Shahzad, M, Lee, S, Ji, JD. The immune regulatory function of B7-H3 in malignancy. Immunologic Research 72(4):526-537, 2024. e-Pub 2024. PMID: 38265550.
- Weinberg BA, Sackstein PE, Yu J, Kim RD, Sommovilla J, Amarnath SR, Krishnamurthi SS. Evolving Standards of Care in the Management of Localized Colorectal Cancer. Am Soc Clin Oncol Educ Book 44(3):e432034, 2024. e-Pub 2024. PMID: 38768426.
- Tojjari A, Yu J, Saeed A. Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473415.
- Tojjari A, Park R, Yu J, Saeed A. Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies. Curr Gastroenterol Rep 26(3):57-67, 2024. e-Pub 2024. PMID: 38294661.
- Yu J, Kim RD. Progress in the treatment of anal cancer: an overview of the latest investigational drugs. Expert Opin Investig Drugs 33(2):145-157, 2024. e-Pub 2024. PMID: 38275174.
- Yu J, Park R, Kim R. Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. J Hepatocell Carcinoma 10:1105-1127, 2023. e-Pub 2023. PMID: 37483311.
- Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. Am Soc Clin Oncol Educ Book 42:1-12, 2022. e-Pub 2022. PMID: 35658496.
- Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 30(4):451-461, 2021. e-Pub 2021. PMID: 33660569.
- Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 14:5145-5160, 2021. e-Pub 2021. PMID: 34720591.
- Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol 155:103091, 2020. e-Pub 2020. PMID: 32961472.
Other Articles
- Park, R, Yu, J, Shahzad, M, Lee, S, Ji, JD Correction to. Immunologic Research 72(4):881, 2024. PMID: 38383812.
Editorials
- Yu J, Saeed A. PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811. Chin Clin Oncol 13(4):59, 2024. PMID: 38859610.
Book Chapters
- Yu, J, Zaytsev, V, Farooq, A, Jalil, A, Wert, J, Ahmed, Z, Ahmad, S. Immunotherapy for hepatocellular cancer, 245-258, 2022.
- Farooq, A, Ahmed, Z, Wert, J, Jalil, A, Yu, J, Zaytsev, V, Ahmad, S. Updates on clinical trials for the management of hepatocellular carcinoma, 259-273, 2022.
Patient Reviews
CV information above last modified October 16, 2025